Alpha 2.0
Login Register
» Authors » M Trypaki

M Trypaki

Explore the profile of M Trypaki including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 5
Citations 170
Followers 0
Related Specialties
Oncology
Pharmacology
Molecular Biology
Top 10 Co-Authors
V Georgoulias
J Souglakos
E Lagoudaki
C Papadaki
E Stathopoulos
D Mavroudis
M Sfakianaki
A Koutsopoulos
E Tsakalaki
K Tryfonidis
Published In
Br J Cancer
Pharmacogenomics J
Affiliations
Soon will be listed here.
Recent Articles
1.
Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer
Tryfonidis K, Papadaki C, Assele S, Lagoudaki E, Menis J, Koutsopoulos A, et al.
Pharmacogenomics J . 2018 Feb; 19(1):15-24. PMID: 29472587
Differences in gene expression levels between the primary tumors (PTs) and matched regional lymph nodal metastases (LNs) in patients with totally excised non-small cell lung cancer (NSCLC) were explored. Microdissected...
2.
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy
Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F, et al.
Pharmacogenomics J . 2016 Oct; 17(6):506-514. PMID: 27779244
To evaluate the predictive value of genes involved in resistance to platinum-taxane chemotherapy in patients with epithelial ovarian cancer (EOC). Microdissected formalin-fixed tumoral samples from 187 EOC patients' primary tumors...
3.
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer
Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, et al.
Br J Cancer . 2014 Sep; 111(9):1757-64. PMID: 25233397
Background: Tumour cells exclusively express the embryonic M2 isoform of pyruvate kinase (PKM2). PKM2 expression levels have been correlated with the effect of platinum compounds in cancer cell lines and...
4.
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
Papadaki C, Tsaroucha E, Kaklamanis L, Lagoudaki E, Trypaki M, Tryfonidis K, et al.
Br J Cancer . 2010 Dec; 104(2):316-23. PMID: 21157449
Background: We explored the predictive significance of BRCA1, TXR1 and TSP1 expression in non-small-cell lung cancer (NSCLC) patients treated with docetaxel in association with cisplatin or gemcitabine. Methods: To analyse...
5.
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al.
Br J Cancer . 2009 Feb; 99(6):923-9. PMID: 19238633
In non-small-cell lung cancer (NSCLC), epidermal growth factor receptor (EGFR) and K-RAS mutations of the primary tumour are associated with responsiveness and resistance to tyrosine kinase inhibitors (TKIs), respectively. However,...